Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70
Hematologic malignancies in older people are unlikely to be cured with chemotherapy
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70
PH Imus, HL Tsai, L Luznik, EJ Fuchs, CA Huff… - Blood Advances, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Hematologic malignancies in older people are
unlikely to be cured with chemotherapy alone. Advances in allogeneic blood or marrow …
unlikely to be cured with chemotherapy alone. Advances in allogeneic blood or marrow …
[HTML][HTML] Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70
PH Imus, HL Tsai, L Luznik, EJ Fuchs, CA Huff… - Blood …, 2019 - ncbi.nlm.nih.gov
Hematologic malignancies in older people are unlikely to be cured with chemotherapy
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70
PH Imus, HL Tsai, L Luznik, EJ Fuchs, CA Huff… - Blood Advances, 2019 - Elsevier
Hematologic malignancies in older people are unlikely to be cured with chemotherapy
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
[PDF][PDF] Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70
BMT Haploidentical - 2019 - academia.edu
The incidence of most hematologic malignancies rises with age, with a median age of onset
in the seventh decade of life. 1 Adverse biologic characteristics in these cancers also …
in the seventh decade of life. 1 Adverse biologic characteristics in these cancers also …
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70
PH Imus, HL Tsai, L Luznik, EJ Fuchs… - Blood …, 2019 - pubmed.ncbi.nlm.nih.gov
Hematologic malignancies in older people are unlikely to be cured with chemotherapy
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70.
PH Imus, HL Tsai, L Luznik, EJ Fuchs, CA Huff… - Blood …, 2019 - europepmc.org
Hematologic malignancies in older people are unlikely to be cured with chemotherapy
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70
PH Imus, HL Tsai, L Luznik, EJ Fuchs… - Blood …, 2019 - pure.johnshopkins.edu
Hematologic malignancies in older people are unlikely to be cured with chemotherapy
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70.
PH Imus, HL Tsai, L Luznik, EJ Fuchs, CA Huff… - Blood …, 2019 - europepmc.org
Hematologic malignancies in older people are unlikely to be cured with chemotherapy
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …
alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially …